Erratum: De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Ann Oncol (2017) 28 (1700–1712) DOI: 10.1093/annonc/mdx308);De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

Annals of Oncology

Volumn 28, Issue 8, 2017, Pages 1700-1712

  Curigliano, Giuseppe ^a   Burstein, H J ^b   Winer, E P ^b   Gnant, M ^c   Dubsky, P ^c,d   Loibl, S ^e   Colleoni, M ^a   M Regan, M ^b   Piccart Gebhart, M ^f   Senn, H J ^g   Thurlimann B ^h   Andre F ⁱ   Baselga, J ^j   Bergh, J ^k   Bonnefoi, H ^l   Brucker, S Y ^m   Cardoso, F ⁿ   Carey, L ^o   Ciruelos, E ^p   Cuzick, J ^q   Denkert, C ^r   Di Leo, A ^s   Ejlertsen, B ^t   Francis, P ^u   Galimberti, V ^a   Garber, J ^b   Gulluoglu, B ^v   Goodwin, P ^w   Harbeck, N ^x   F Hayes, D ^y   Huang, C S ^z   Huober, J ^aa   Hussein, K ^ab   Jassem, J ^ac   Jiang, Z ^ad   Karlsson, P ^ae   Morrow, M ^j   Orecchia, R ^a   Osborne, K C ^af   Pagani, O ^ag   Partridge, A H ^b   Pritchard, K ^ah   Ro, J ^ai   Rutgers, E J T ^aj   Sedlmayer, F ^ak   Semiglazov, V ^al   Shao, Z ^am   Smith, I ^an   Toi, M ^ao   Tutt, A ^ap   Viale, G ^a,aq   Watanabe, T ^ar   Whelan, T J ^as   Xu, B ^at   more..

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d Klinik St Anna   (Switzerland)

^e GERMAN BREAST GROUP   (Germany)

^f JULES BORDET INSTITUTE   (Belgium)

^g Tumor Center ZeTuP   (Switzerland)

^h CANTONAL HOSPITAL ST GALLEN   (Switzerland)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k KAROLINSKA INSTITUTE   (Sweden)

^l UNIVERSITÉ DE BORDEAUX   (France)

^m UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

ⁿ Champalimaud Cancer Centre   (Portugal)

^o UNIVERSITY OF NORTH CAROLINA   (United States)

^p HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^q QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^r CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^s SOS Allergology and Clinical Immunology   (Italy)

^t University of Copenhagen   (Denmark)

^u PETER MACCALLUM CANCER CENTRE   (Australia)

^v MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^w UNIVERSITY OF TORONTO   (Canada)

^x UNIVERSITY OF MUNICH   (Germany)

^y UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^z NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^aa UNIVERSITY OF ULM   (Germany)

^ab CAIRO UNIVERSITY   (Egypt)

^ac MEDICAL UNIVERSITY OF GDANSK   (Poland)

^ad Affiliated Hospital of Military Medical Academy of Sciences   (China)

^ae SAHLGRENSKA ACADEMY AT UNIVERSITY OF GOTHENBURG   (Sweden)

^af BAYLOR COLLEGE OF MEDICINE   (United States)

^ag OSPEDALE SAN GIOVANNI   (Switzerland)

^ah DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^ai National Cancer Center   (South Korea)

^aj ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^ak PARACELSUS MEDICAL UNIVERSITY   (Austria)

^al N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^am FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^an Royal Marsden Hospital   (United Kingdom)

^ao KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^ap INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^aq UNIVERSITY OF MILAN   (Italy)

^ar Hamamatsu Oncology Center   (Japan)

^as MCMASTER UNIVERSITY   (Canada)

^at National Cancer Center   (China)

more..

Author keywords

Early breast cancer; Radiation therapy; St Gallen Consensus; Surgery; Systemic adjuvant therapies

Indexed keywords

DENOSUMAB; TAMOXIFEN; ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT;

ADJUVANT BONE MODIFYING THERAPY; ADJUVANT THERAPY; ARTICLE; AXILLARY SURGERY; BREAST CANCER; BREAST CANCER MOLECULAR SUBTYPE; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG INDICATION; EARLY CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENETIC SCREENING; GENOMICS; GROUPS BY AGE; HEREDITARY TUMOR SYNDROME; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; INTRADUCTAL CARCINOMA; MALE BREAST CANCER; NEOADJUVANT THERAPY; ONCOLOGY; PATIENT SELECTION; POSTMENOPAUSE; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOLOGY; AUSTRIA; BREAST TUMOR; CONSENSUS DEVELOPMENT; EARLY DIAGNOSIS; FEMALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RADIOTHERAPY; SURGERY;

ADJUVANTS, IMMUNOLOGIC; ANTINEOPLASTIC AGENTS; AUSTRIA; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; EARLY DIAGNOSIS; FEMALE; HUMANS; NEOADJUVANT THERAPY; RADIOTHERAPY; SURGICAL PROCEDURES, OPERATIVE;

EID: 85029311382     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx806     Document Type: Erratum

References (90)

1. Burstein HJ, Polyak K, Wong JS et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430-1441
2. Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcome of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103: 478-488
3. Morrow M, Van Zee KJ, Solin LJ et al. Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol 2016; 34: 4040-4046
4. Forbes JF, Sestak I, Howell A et al. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet 2016; 387: 866-873
5. Margolese RG, Cecchini RS, Julian TB et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, doubleblind, phase 3 clinical trial. Lancet 2016; 387: 849-856
6. Moran MS, Schnitt SJ, Giuliano AE et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol 2014; 32: 1507-1515
7. De La Cruz L, Moody AM, Tappy EE et al. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol 2015; 22: 3241-3249
8. Giuliano AE, Hunt KK, Ballman KV et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011; 305: 569-575
9. Ataseven B, Lederer B, Blohmer JU. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 2015; 22: 1118-1127
10. Santoro S, Loreti A, Cavaliere F. Neoadjuvant chemotherapy is not a contraindication for nipple sparingmastectomy. Breast 2015; 24: 661-666
11. Kuehn T, Bauerfeind I, Fehm T et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013; 14: 609-618
12. Boughey JC, Suman VJ, Mittendorf EA. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013; 310(14): 1455-1461
13. Boileau JF, Poirier B, Basik M et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015; 33: 258-264
14. Mamtani A, Barrio AV, King TA et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol 2016; 23: 3467-3474
15. El Hage Chehade H, Headon H, El Tokhy O et al. Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg 2016; 212: 969-981
16. Whelan TJ, Pignol JP, Levine MN et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362: 513-520
17. Correa C, Harris EE, Leonardi MC, et al. Accelerated partial breast irradiation: executive summary for the update of an ASTRO evidence-based consensus statement. Pract Rad Oncol 2017; 7: 73-79
18. Bartelink H, Maingon P, Poortmans P et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol 2015; 16: 47-56
19. Vrieling C, van Werkhoven E, Maingon P et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC boost vs no boost trial: a randomized clinical trial. JAMA Oncol 2017; 3: 42-48
20. Whelan TJ, Olivotto IA, Parulekar WR et al. MA.20 Study Investigators. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015; 373: 307-316
21. Poortmans PM, Collette S, Kirkove C et al. EORTC Radiation Oncology and Breast Cancer Groups. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373: 317-327
22. Harris LN, Ismaila N, McShane LM et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34: 1134-1150
23. Sparano JA, Gray RJ, Makower DF et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 2015; 373: 2005-2014
24. Gluz O, Nitz UA, ChristgenM et al. West German Study Group Phase III PlanB Trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol 2016; 34: 2341-2349
25. Cardoso F, van't Veer LJ, Bogaerts J et al. MINDACT Investigators. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016; 375: 717-729
26. Gnant M, Filipits M, Greil R et al. Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 2014; 25: 339-345
27. Filipits M, Rudas M, Jakesz R et al. EP Investigators. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17: 6012-6020
28. GnantM, Sestak I, FilipitsMet al. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Ann Oncol 2015; 26: 1685-1691
29. Early Breast Cancer Trialists Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100,000 women in 123 randomized trials. Lancet 2012; 379: 432-444
30. Sgroi DC, Sestak I, Cuzick J et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14: 1067-1076
31. Dubsky P, Brase JC, Jakesz R et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2-breast cancer patients. Br J Cancer 2013; 109(12): 2959-2964
32. Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446
33. Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118
34. Gnant M, Mlineritsch B, Stoeger H et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 2012; 6: 313-320
35. Burstein HJ, Temin S, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014; 32: 2255-2269
36. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; 386(10001): 1341-1352
37. Metzger Filho O, Giobbie-Hurder A, Mallon E et al. Relative effectiveness of letrozole compared With tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial. J Clin Oncol 2015; 33(25): 2772-2779
38. Goss PE, Ingle JN, Pritchard KI et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016; 375(3): 209-219
39. Tjan-Heijnen VC, Van Hellemond IE, Peer PG et al. First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer. In San Antonio Breast Cancer Symposium2016, 6-10 December 2016, San Antonio, TX (abstr S1-03)
40. Blok EJ, van de Velde CJH, Meershoek-Klein Kranenbarg EM et al. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05). In San Antonio Breast Cancer Symposium 2016, 6-10 December 2016, San Antonio, TX (abstr S1-04)
41. Mamounas EP, Bandos H, Lembersky BC et al. A randomized, doubleblinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. San Antonio Breast Cancer Symposium 2016, 2016 Dec 6-10, San Antonio, TX (abstr S1-05)
42. Masuda N, Lee SJ, Ohtani S et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 2017; 376(22): 2147-2159
43. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 2015; 386(10001): 1353-1361; Erratum Lancet 2016; 387(10013): 30
44. Gnant M, Pfeiler G, Dubsky PC et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 433-443
45. Nangia JR, Wang T, Niravath PA et al. Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer. In San Antonio Breast Cancer Symposium 2016, 6-10 December 2016, San Antonio, TX (abstr S5-02)
46. Kurian AW, Hare EE, Mills MA et al. Clinical evaluation of a multiplegene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014; 32(19): 2001-2009
47. Strnad V, Ott OJ, Hildebrandt G et al. Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO). 5-Year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet 2016; 387(10015): 229-238
48. Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 2015; 33(1): 13-21
49. Rugo HS, Olopade OI, DeMichele A et al. I-SPY 2 Investigators. Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 2016; 375(1): 23-34
50. Untch M, Jackisch C, Schneeweiss A et al. German Breast Group (GBG), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 2016; 17(3): 345-356
51. Gianni L, Mansutti M, Anton A et al. ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: a MICHELANGO study. J Clin Oncol 2016; 34(suppl): abstr 502
52. Gianni L, Pienkowski T, Im YH et al. 5-Year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17(6): 791-800
53. Hurvitz SA, Martin M, Symmans WF et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). J Clin Oncol 2016; 34(suppl): abstr 500
54. Park JW, Liu MC, Yee D et al. I-SPY 2 Investigators. Adaptive randomization of neratinib in early breast cancer. N Engl JMed 2016; 375(1): 11-22
55. Curigliano G, Gómez Pardo P, Meric-Bernstam F et al. Ribociclib plus letrozole in early breast cancer: a presurgical, window-of-opportunity study. Breast 2016; 28: 191-198
56. Ma CX, Gao F, Luo J et al. NeoPalAna: neoadjuvant palbociclib, a cyclindependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer. Clin Cancer Res 2017 [epub ahead of print], pii:clincanres.3206.2016, doi: 10.1158/1078-0432.CCR-16-3206
57. Hurvitz S, Abad MF, Rostorfor R et al. Interim results from neoMONARCH: a neoadjuvant phase II study of abemaciclib in postmenopausal women with HR +/HER2-breast cancer (BC). Ann Oncol 2016; 27(suppl_6): LBA13
58. Bear HDD, Wan W, Robidoux A et al. Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: a multicenter trial. In San Antonio Breast Cancer Symposium 2016, 6-10 December 2016, San Antonio, TX (abstr P2-10-04)
59. Blum JL, Flyn PJ, Yothers G et al. Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer. J Clin Oncol 2016; 34: (suppl; abstr 1000)
60. Bell R, Brown J, Parmar M et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol 2016; 28(4): 754-760
61. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R et al. Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer: the randomized clinical FinXX trial. JAMA Oncol 2017; 3(6): 793-800
62. Del Mastro L, De Placido S, Bruzzi P et al. Gruppo Italiano Mammella (GIM) investigators. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial. Lancet 2015; 385(9980): 1863-1872
63. Foukakis T, von Minckwitz G, Bengtsson NO et al. Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer: a randomized clinical trial. JAMA 2016; 316(18): 1888-1896
64. Piccart-GebhartM, Holmes E, Baselga J et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016; 34(10): 1034-1042
65. Chan A, Delaloge S, Holmes FA et al. ExteNET Study Group. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17(3): 367-377
66. van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM et al. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat 2016; 158(2): 361-371. Erratum in Breast Cancer Res Treat 2016;159(2): 393
67. Tolaney SM, Barry WT, Dang CT et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015; 372(2): 134-141
68. Ribi K, Luo W, Bernhard J et al. Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 2016; 34(14): 1601-1610
69. Smith I, Yardley D, Burris H et al. Comparative efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor-positive, node-positive early breast cancer: final results of the randomized phase III femara versus anastrozole clinical evaluation (FACE) trial. J Clin Oncol 2017; 35(10): 1041-1048
70. Rugo HS, Klein P, Melin SA et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 2017; 317(6): 606-614
71. Henry NL, Unger JM, Schott AF et al. Randomized, placebo-controlled trial of duloxetine for aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in early stage breast cancer (SWOG S1202). In San Antonio Breast Cancer Symposium 2016, 6-10 December 2016, San Antonio, TX (abstr S5-06)
72. Nanda R, Chow LQ, Dees EC et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016; 34(21): 2460-2467
73. Dirix LY, Takacs I, Nikolinakos P et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. In San Antonio Breast Cancer Symposium 2015, 8-12 December 2015, San Antonio, TX (abstr S1-04)
74. Adams S, Diamond JR, Hamilton EP. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2016; 34: (suppl; abstr 1009)
75. Finn RS, Martin M, Rugo HS et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016; 375(20): 1925-1936
76. Turner NC, Ro J, André F et al. PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015; 373(3): 209-219
77. Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016; 375(18): 1738-1748
78. Perez EA, Barrios C, Eiermann W et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase IIIMARIANNE study. J Clin Oncol 2017; 35(2): 141-148
79. Urruticoechea A, Rizwanullah M, Im SA et al. PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) 6 pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. J Clin Oncol 2016; 34: (suppl): abstr 504
80. Arpino G, Ferrero J-M, de la Haba-Rodriguez J et al. Primary analysis of PERTAIN: a randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first-line patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. In San Antonio Breast Cancer Symposium 2016, 6-10 December 2016, San Antonio, TX (abstr S3-04)
81. Fribbens C, O'Leary B, Kilburn L et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016; 34(25): 2961-2968
82. Tutt A, Ellis P, Kilburn L et al. TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). In San Antonio Breast Cancer Symposium 2014, 9-13 December 2014, San Antonio, TX (abstr S3-01)
83. Diéras V, Han HS, Robson MEE et al. Evaluation of veliparib (V) and temozolomide (TMZ) in a phase 2 randomized study of the efficacy and tolerability of V+TMZ or carboplatin (C) and paclitaxel (P) vs placebo (Plc)+C/P in patients (pts) with BRCA1 or BRCA2 mutations and metastatic breast cancer. In San Antonio Breast Cancer Symposium 2016, 6-10 December 2016, San Antonio, TX (abstr P4-22-02)
84. Baselga J, Im S-A, Iwata H et al. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/ HER2-advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial. San Antonio Breast Cancer Symposium 2015, 8-12 December 2015, San Antonio, TX (abstr S6-01)
85. Di Leo A, Seok Lee K, Ciruelos E et al. BELLE-3: A phase III study of buparlisib+fulvestrant in postmenopausal women with HR+, HER2-, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. In San Antonio Breast Cancer Symposium 2016, 6-10 December 2016, San Antonio, TX (abstr S4-07)
86. Krop IE, Mayer IA, Ganju V et al. Pictilisib for oestrogen receptorpositive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17(6): 811-821
87. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360: 679-691
88. Polley MY, Leung SC, Gao D et al. An international study to increase concordance in Ki67 scoring. Mod Pathol 2015; 28: 778-786
89. Polley MY, Leung SC, McShane LM et al. An international ki67 reproducibility study. J Natl Cancer Inst 2013; 105: 1897-1906
90. von Minckwitz G, Procter M, de Azambuja E et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 2017; 377(2): 122-131